Medical Licensing (MD/DO) · Independent exam preparation
ABIM Hematology Certification: Clinical Decisions Guide Study Guide
Practise anemia workups, bleeding and thrombosis decisions, malignancy classification, and transfusion and cellular therapy safety for ABIM hematology.
By CertMedbry · Updated 18 October 2026
Distinguish iron depletion from impaired iron use, interpret bleeding and thrombosis tests, classify hematologic malignancies, and recognize treatment emergencies. These 60 selected concepts connect mechanisms to clinical decisions across all five certification domains. The January 2026 ABIM Hematology Certification Examination blueprint defines the full scope; this guide provides a selective foundation rather than complete coverage.
Try 20 free practice questionsWhat is the exam format?
Check the question types, timing and outline before planning your revision.
Which examination and certification level does this guide address?
The Hematology Certification Examination is administered by the American Board of Internal Medicine for physician subspecialty certification. Previously obtained ABIM internal medicine certification is an admission requirement. The listing name 'ABIM - Subspecialty in Hematology' refers to this examination; it does not identify a separate examination or a historical renamed credential. This is a United States physician board certification assessment, not a medical licensure examination.
Which blueprint applies, and what are its domain weights?
The certification blueprint prints January 2026 and is linked from ABIM's certification blueprint index. It states no separate effective date. Its typical examination allocation is Hematopoietic System 25%, Coagulation 27%, Hematologic Neoplastic Disorders 35%, Transfusion Medicine 5%, and Cellular Therapy 8%. Pregnancy and contraception overlap the domains at approximately 4%. Actual examination content may vary. The official nine-page outline remains the full scope.
Hematology Blueprint — Certification Examination (CERT), January 2026 · ABIM Blueprints
How many questions are included, and which questions count toward the score?
The blueprint specifies up to 240 single-best-answer multiple-choice questions, including approximately 40 new questions that do not count toward the examinee's score. ABIM describes four sessions containing up to 60 questions each. These figures should not be converted into a guaranteed exact scored-question count.
Hematology Blueprint — Certification Examination (CERT), January 2026 · Register, Prepare and Take Your Subspecialty Certification Exam — Hematology
How long is the examination day?
ABIM describes an approximately 10-hour examination day. Each of four testing sessions allows up to two hours, giving up to eight hours of question time. The schedule also includes an optional tutorial of up to 30 minutes, instructions, and 100 total minutes of break time shared among three breaks. Individual accommodations may alter scheduling.
Register, Prepare and Take Your Subspecialty Certification Exam — Hematology
How is the examination delivered, and what item styles should candidates expect?
Candidates schedule a Pearson VUE test-center appointment through ABIM's registration process. The examination uses single-best-answer MCQs, predominantly patient scenarios, and may include photographs, radiographs, blood films, or other media. ABIM describes multiple examination forms and scheduled sessions; its examination information does not establish item-by-item adaptive delivery. The 20 exercises here are independent four-option MCQ drills.
Register, Prepare and Take Your Subspecialty Certification Exam — Hematology · Hematology Blueprint — Certification Examination (CERT), January 2026
Does this guide also cover hematology MOC or focused LKA pathways?
The selected pathway is initial hematology certification. ABIM separately lists Hematology General LKA and classical and malignant focus LKAs under maintenance-of-certification assessment blueprints. Those assessments have their own specifications; their scope and logistics should not be substituted for the certification blueprint used here.
What examination date and scoring details are verified?
ABIM lists November 17, 2026 for the standard 2026 Hematology Certification Examination administration, with dates subject to change. ABIM bases the pass-fail decision on overall examination performance and an absolute standard, and scores unanswered questions as incorrect. No numerical passing score or examination fee is asserted here.
Register, Prepare and Take Your Subspecialty Certification Exam — Hematology
This independent educational guide addresses ABIM physician subspecialty certification in hematology. Its original questions and flashcards are learning exercises and do not predict examination performance.
Outline used: ABIM Hematology Blueprint, Certification Examination (CERT), January 2026; current certification blueprint linked by ABIM and opened on 2026-10-09. The document prints January 2026 but does not state a separate effective date. The workbook label 'ABIM - Subspecialty in Hematology' maps to ABIM's Hematology Certification Examination; the assigned slug is preserved.
60 key concepts: understand, apply and avoid the traps
Work through the questions by exam domain. Explain the answer in your own words, try the example, then check the common pitfall.
Hematopoietic System25%
1.How does a low ferritin establish iron depletion?
Ferritin reflects stored iron, so a clearly reduced concentration supports depletion rather than merely reduced circulating iron. Hemoglobin establishes whether anemia is present, while cell size describes its morphology. These measurements answer different questions: iron deficiency can precede anemia, and microcytosis alone does not establish its cause. Interpret ferritin with the clinical setting because inflammation can complicate the relationship between measured ferritin and usable iron.
Apply it
A patient with fatigue has hemoglobin 10.2 g/dL, microcytosis, and ferritin 6 micrograms/L. Identify depleted iron stores, then investigate why iron is being lost or inadequately absorbed while planning replacement.
Common pitfall: Choosing iron deficiency solely from microcytosis overlooks other causes. Conversely, a hemoglobin within the reference range does not prove that iron stores are adequate.
2.Why must iron replacement be paired with a cause assessment?
Iron replacement treats the deficit but does not explain its origin. Chronic gastrointestinal bleeding, heavy menstrual bleeding, gastrointestinal disease, and impaired absorption can each produce iron deficiency. Medication history matters because aspirin and other nonsteroidal anti-inflammatory drugs can contribute to gastrointestinal loss. Oral iron is commonly used, while intravenous iron bypasses gastrointestinal uptake when absorption or intolerance limits treatment. Red-cell transfusion rapidly supports circulating red-cell mass but does not resolve the cause or replace a plan for iron repletion.
Apply it
An older adult develops recurrent deficiency after initially responding to supplements. Regular naproxen use and epigastric symptoms warrant assessment for gastrointestinal loss. If oral iron is ineffective or intolerable, intravenous replacement can address delivery while the cause is investigated.
Common pitfall: A response to iron confirms that replacement helped erythropoiesis; it does not establish that the bleeding or absorption problem has resolved. Intravenous iron also does not provide an immediate transfusion-equivalent hemoglobin increase.
3.Which findings distinguish beta-thalassemia trait from iron deficiency?
Thalassemia reduces globin-chain production rather than iron supply. Persistent microcytosis with adequate iron stores should prompt hemoglobin analysis. An increased HbA2, commonly above 3.5% with laboratory-specific interpretation, supports typical beta-thalassemia trait. A borderline result requires further assessment; iron deficiency can coexist and complicate interpretation. Integrate indices, iron studies, hemoglobin fractions, and family history rather than diagnosing either condition from MCV alone. See the [Thalassaemia International Federation laboratory recommendations](https://www.thalassaemia.org.cy/wp-content/uploads/2017/08/PreventionVol2_English.pdf).
Apply it
An adult has longstanding mild anemia, MCV 65 fL, adequate ferritin, and HbA2 5.2%. The combination favors beta-thalassemia trait over isolated iron deficiency.
Common pitfall: Microcytosis does not establish iron deficiency. A normal or borderline HbA2 also cannot exclude every beta-thalassemia variant.
Hematology Blueprint — Certification Examination (CERT), January 2026
4.How can inflammation restrict iron use despite preserved stores?
Inflammation increases hepcidin, a liver-derived regulator that binds ferroportin and inhibits iron export from cells. This reduces intestinal iron absorption and release of recycled iron from macrophages. Circulating iron and iron available for erythropoiesis can therefore fall despite preserved or increased stores. Ferritin may remain normal or increase because iron is sequestered and ferritin also responds to inflammation. Absolute iron depletion can coexist, especially with gastrointestinal or menstrual loss.
Apply it
A patient with active inflammatory bowel disease has anemia, low circulating iron, and elevated ferritin. Consider hepcidin-mediated sequestration while assessing gastrointestinal loss; elevated ferritin does not reliably exclude a concurrent deficit during inflammation.
Common pitfall: Low serum iron does not distinguish sequestration from depleted stores. Conversely, an elevated ferritin during inflammation does not guarantee that iron delivery to the marrow is adequate.
The Double-edged Sword of Hepcidin - NIDDK · NHLBI: Iron-Deficiency Anemia
5.How do alpha-globin gene losses distinguish alpha-thalassemia trait from hemoglobin H disease?
There are normally four alpha-globin genes. In deletional alpha-thalassemia, loss of two causes trait, whereas loss of three usually produces hemoglobin H disease with more substantial anemia. Adult hemoglobin electrophoresis can be normal in alpha-thalassemia trait; persistent microcytosis with adequate iron and normal HbA2 therefore warrants consideration of alpha-globin testing. See [NHLBI's inheritance explanation](https://www.nhlbi.nih.gov/health/thalassemia/causes) and the [TIF laboratory recommendations](https://www.thalassaemia.org.cy/wp-content/uploads/2017/08/PreventionVol2_English.pdf).
Apply it
A patient has persistent microcytosis, adequate iron, and normal hemoglobin fractions. Alpha-globin testing identifies two deleted genes, supporting alpha-thalassemia trait.
Common pitfall: Normal electrophoresis does not exclude alpha-thalassemia trait. Gene-count rules describe common deletional forms; nondeletional variants can alter severity.
Hematology Blueprint — Certification Examination (CERT), January 2026
6.How do absorption failure and neurologic findings guide vitamin B12 assessment?
Intrinsic factor is a stomach-derived protein that enables effective intestinal vitamin B12 absorption. Pernicious anemia and gastric surgery can impair this pathway despite adequate dietary intake. Vitamin B12 deficiency affects blood-cell formation and nervous-system function: multilineage cytopenias, paresthesias, impaired walking, or cognitive changes can accompany anemia. Neurologic injury may persist after correction, so urgency cannot be judged from hemoglobin alone. Identifying an ongoing absorption defect also helps explain why replacement may need to be sustained.
Apply it
A patient who eats meat regularly develops anemia, leukopenia, thrombocytopenia, tingling, and gait difficulty after gastrectomy. Assess vitamin B12 deficiency as a potentially reversible cause of the blood-count abnormalities and promptly address the neurologic manifestations.
Common pitfall: Adequate intake does not prove adequate absorption. Multiple cytopenias do not automatically establish a marrow neoplasm, and hematologic recovery does not guarantee complete neurologic recovery.
7.Which mechanism and antibody pattern favor warm autoimmune hemolytic anemia?
Warm AIHA usually involves IgG reacting near 37°C. Splenic phagocytes recognize antibody-coated red cells through Fc receptors, causing predominantly extravascular destruction. Demonstrated hemolysis with an IgG-positive direct antiglobulin test supports the diagnosis. Corticosteroids are initial treatment; severe disease or inadequate response can justify early rituximab. See the [mechanistic study](https://haematologica.org/article/view/7553) and [international consensus recommendations](https://mayoclinic.elsevierpure.com/en/publications/diagnosis-and-treatment-of-autoimmune-hemolytic-anemia-in-adults-/).
Apply it
An anemic patient has increased indirect bilirubin and LDH, reduced haptoglobin, and an IgG-positive DAT. Together these favor warm immune hemolysis.
Common pitfall: A positive DAT alone does not establish active hemolysis. Complement can accompany warm AIHA, so C3 positivity alone does not classify the antibody.
Hematology Blueprint — Certification Examination (CERT), January 2026
8.How does cold antibody-mediated hemolysis differ from warm AIHA?
Cold-reactive IgM activates complement on red cells, causing complement-mediated clearance or intravascular lysis. Hemolysis with a complement-positive DAT and clinically significant cold-reactive antibodies supports this mechanism. Prednisone usually works poorly, unlike in warm AIHA; protection from cold and disease-directed therapy address different aspects of care. See the [mechanistic study](https://haematologica.org/article/view/7553).
Apply it
A patient has hemolysis, cold-associated red-cell agglutination, a C3-positive/IgG-negative DAT, and a clinically significant cold antibody. These favor cold antibody-mediated hemolysis.
Common pitfall: Complement positivity is not specific for cold disease. Confirm the antibody's clinical significance before assigning the subtype or extending a warm-AIHA steroid strategy.
Hematology Blueprint — Certification Examination (CERT), January 2026
9.How do oxidative exposures trigger hemolysis in G6PD deficiency?
G6PD helps protect red cells from oxidative damage. Deficiency leaves them vulnerable when oxidant stress rises, including during infection or after certain medicines or fava-bean exposure. Hemolysis may therefore be episodic, with an exposure preceding jaundice, dark urine, fatigue, or worsening anemia. The useful diagnostic connection is the temporal relationship between stress and red-cell destruction, rather than assuming that an inherited disorder must cause continuously severe anemia between episodes.
Apply it
A patient develops dark urine and jaundice during an infection after starting a new medicine. Review whether oxidative stress could have precipitated hemolysis in previously unrecognized G6PD deficiency and identify the implicated exposure.
Common pitfall: Absence of chronic anemia does not exclude an inherited enzyme defect. Infection itself can supply oxidative stress even when no new medication is identified.
MedlinePlus Genetics: Glucose-6-Phosphate Dehydrogenase Deficiency
10.How does X-linked inheritance shape G6PD counseling?
The G6PD gene lies on the X chromosome. A male with a disease-associated variant on his single X chromosome can express deficiency, while females can also be affected depending on their genetic constitution and X-chromosome inactivation. An affected father transmits his X chromosome to daughters rather than sons. Family assessment should therefore follow X-linked transmission rather than assuming equal father-to-child transmission across sexes or excluding clinically affected females.
Apply it
An affected father asks whether his son inherited the same G6PD variant directly from him. Explain that sons receive the paternal Y chromosome, whereas daughters receive his X chromosome and its associated variant.
Common pitfall: Using a simple male-only model is misleading because females can express deficiency. Father-to-son transmission is also inconsistent with an X-linked location for the variant.
MedlinePlus Genetics: Glucose-6-Phosphate Dehydrogenase Deficiency
11.Which flow-cytometry findings support a PNH population?
PNH testing identifies cells deficient in glycosylphosphatidylinositol-linked structures. In leukocyte assays, FLAER binding is assessed alongside lineage-appropriate GPI-linked markers, such as CD24 on neutrophils and CD14 on monocytes. Lineage gating is essential because marker expression normally differs among cell types. Concordant deficiency in properly identified populations is more persuasive than loss of a single marker in an uncertain gate, which may reflect normal biology or technical error. A small clone above validated assay limits requires clinical correlation and does not independently establish clinically dominant hemolytic PNH.
Apply it
A specimen contains neutrophils lacking FLAER binding and CD24, with a corresponding monocyte population lacking FLAER binding and CD14. This coordinated pattern supports a GPI-deficient population rather than an isolated antigen-expression anomaly.
Common pitfall: A marker absent from the wrong lineage is not diagnostic. Interpret GPI-marker loss only after confirming cell identity and the adequacy of normal internal controls.
ICCS/ESCCA Consensus Guidelines for PNH Flow Cytometry, Part 4
12.Which findings make aplastic anemia a marrow-failure problem requiring treatment planning?
Aplastic anemia results from loss or injury of hematopoietic stem cells, commonly through immune-mediated destruction. Reduced marrow cellularity with anemia, neutropenia, and thrombocytopenia points to deficient production across lineages. Assess marrow findings, exposures, and inherited causes rather than assuming every pancytopenia is acquired aplasia. Transfusion support does not restore the stem-cell compartment. Disease-directed planning considers transplantation versus immunosuppression according to age and matched-donor availability; ASH's 2026 guidance supports adding eltrombopag to standard immunosuppression. See [NHLBI's aplastic anemia overview](https://www.nhlbi.nih.gov/health/anemia/aplastic-anemia) and [ASH's acquired aplastic anemia recommendations](https://www.hematology.org/newsroom/press-releases/2026/ash-guidelines-on-severe-acquired-aplastic-anemia).
Apply it
A patient with recurrent infections and bruising has pancytopenia and a markedly hypocellular marrow. Evaluate aplastic anemia and its mimics, begin supportive care, and assess age and donor availability promptly to guide definitive treatment.
Common pitfall: The term anemia can obscure infection and bleeding risk from other cytopenias. Hypocellularity alone does not exclude hypoplastic MDS or an inherited marrow-failure syndrome.
Hematology Blueprint — Certification Examination (CERT), January 2026
13.When does severe acute chest syndrome favor red-cell exchange?
For severe acute chest syndrome in sickle cell disease, ASH favors automated or manual red-cell exchange over simple transfusion. Exchange removes circulating patient red cells while replacing them with donor cells, reducing the sickling-cell burden without relying solely on increasing total red-cell mass. Worsening hypoxemia or rapidly progressive disease strengthens the distinction from a stable, less severe presentation. The recommendation is conditional and should be interpreted within the patient's clinical trajectory.
Apply it
A patient with sickle cell disease develops expanding pulmonary infiltrates and escalating oxygen requirements despite initial care. Treat the trajectory as severe acute chest syndrome and arrange red-cell exchange with the appropriate clinical teams.
Common pitfall: Selecting simple transfusion automatically because anemia is present ignores severity and progression. Raising total hemoglobin alone may not achieve the intended reduction in sickling-cell burden.
14.How does antigen matching reduce transfusion harm in sickle cell disease?
Repeated exposure to unfamiliar red-cell antigens can produce alloantibodies and make subsequent transfusions difficult or hazardous. ASH recommends prophylactic matching for Rh C/E or C/c/E/e and K rather than ABO/RhD matching alone. An extended antigen profile obtained early supports future compatibility work. Genotyping is useful when recent transfusion makes serologic phenotyping unreliable because circulating donor red cells can obscure the patient's own antigen pattern.
Apply it
A patient with sickle cell disease needs a first planned transfusion. Obtain an extended antigen profile and arrange prophylactic Rh and K matching, establishing useful compatibility information before repeated donor-cell exposure complicates later testing.
Common pitfall: ABO and RhD compatibility do not eliminate clinically important alloimmunization. A serologic phenotype soon after transfusion may partly describe donor cells rather than the patient.
15.Which posttransfusion pattern identifies hyperhemolysis in sickle cell disease?
Hyperhemolysis is characterized by a rapid hemoglobin decline below the pretransfusion level with a rapid decline in posttransfusion hemoglobin A. It can accompany a delayed hemolytic transfusion reaction and may occur without an identifiable alloantibody or positive direct antiglobulin test. The important decision is to recognize destruction beyond a simple failure to retain the expected transfusion increment. Additional transfusion requires particular caution because it may aggravate the process.
Apply it
Eight days after transfusion, a patient with sickle cell disease develops hemoglobinuria and hemoglobin below the pretransfusion baseline, with falling hemoglobin A. Recognize hyperhemolysis despite a negative direct antiglobulin test and reassess further transfusion.
Common pitfall: A negative antibody investigation does not exclude hyperhemolysis. Reflexively transfusing to correct every falling hemoglobin may worsen the reaction when anemia is not immediately life-threatening.
Coagulation27%
16.How is each component of the 4Ts score calculated?
Assign 2, 1, or 0 points per component. Thrombocytopenia: 2 for a fall >50% with nadir ≥20 × 10^9/L; 1 for a fall 30–50% or nadir 10–19; 0 for a fall <30% or nadir <10. Timing: 2 for clear onset on days 5–14 or within one day after heparin exposure within 30 days; 1 for an unclear but compatible days 5–14 onset, onset after day 14, or a fall within one day after exposure 30–100 days earlier; 0 for onset within four days without recent exposure. Thrombosis/sequelae: 2 for confirmed new thrombosis, injection-site necrosis, anaphylactoid reaction after IV heparin, or adrenal hemorrhage; 1 for progressive/recurrent thrombosis, suspected unconfirmed thrombosis, or nonnecrotizing skin lesions; 0 for none. Other causes: 2 if none apparent, 1 if possible, 0 if definite. Totals 0–3, 4–5, and 6–8 indicate low, intermediate, and high probability.
Apply it
Platelets fall from 320 to 130 × 10^9/L: (320−130)/320×100 = 59.4%. Onset on day seven, confirmed new thrombosis, and no alternative cause give 2+2+2+2 = 8 points.
Common pitfall: The relative fall matters even when platelets remain above 150 × 10^9/L. Obtain missing exposure and count data and recalculate when the clinical picture changes.
ASH: Diagnosis and Management of Heparin-Induced Thrombocytopenia
17.When should suspected HIT change anticoagulation before confirmation?
Intermediate- or high-probability HIT generally requires stopping heparin and starting a non-heparin anticoagulant while laboratory evaluation proceeds. High-probability presentations warrant therapeutic intensity. For intermediate probability without another therapeutic indication, bleeding risk affects the initial intensity. Conversely, ASH recommends against routine HIT testing or empiric HIT treatment with a reliable low-probability score. The immediate decision follows clinical probability and thrombotic risk rather than waiting passively for an antibody result.
Apply it
A heparin-treated patient develops a greater than 50% platelet fall and a new proximal deep-vein thrombosis on day six. Stop heparin and initiate appropriate therapeutic non-heparin anticoagulation while sending the indicated HIT tests.
Common pitfall: Stopping heparin alone leaves a strongly prothrombotic disorder untreated. Replacing unfractionated heparin with low-molecular-weight heparin does not provide an appropriate non-heparin strategy.
ASH: Diagnosis and Management of Heparin-Induced Thrombocytopenia
18.Why do HIT immunoassays and functional assays answer different questions?
HIT immunoassays detect antibodies against PF4/heparin complexes, including antibodies that may not activate platelets. Functional assays examine whether antibodies cause the platelet activation responsible for clinical HIT. A positive immunoassay therefore requires interpretation alongside the 4Ts score and assay strength. Functional testing is usually useful after a positive immunoassay when available, although a high clinical probability with a strongly positive immunoassay can sometimes support management without it.
Apply it
A patient with a weakly positive PF4 immunoassay has several plausible non-HIT causes of thrombocytopenia. Recheck the clinical probability and obtain functional testing when indicated rather than treating antibody detection as proof of pathogenic activation.
Common pitfall: Equating every positive antibody assay with HIT confuses binding with biological activity. A negative functional result also warrants scrutiny when the clinical and immunoassay evidence is exceptionally strong.
ASH: Diagnosis and Management of Heparin-Induced Thrombocytopenia
19.How does severe ADAMTS13 deficiency identify TTP?
ADAMTS13 cleaves large von Willebrand factor multimers. Severe deficiency permits platelet-rich microvascular thrombosis, producing thrombocytopenia and microangiopathic hemolytic anemia. Activity below 10% strongly supports TTP in the appropriate clinical setting. Measuring an inhibitor or anti-ADAMTS13 antibody helps identify an immune mechanism. The syndrome should be considered from its hematologic and organ-injury pattern rather than requiring every feature of the historical clinical pentad before acting.
Apply it
A patient has severe thrombocytopenia, schistocytes, hemolysis, and fluctuating confusion. An ADAMTS13 activity of 3% with an inhibitor supports immune TTP and explains the combination of platelet consumption and microvascular organ injury.
Common pitfall: Waiting for the complete historical pentad delays recognition. Schistocytes identify a microangiopathic process but do not independently establish which thrombotic microangiopathy is present.
ISTH Guidelines for the Diagnosis of Thrombotic Thrombocytopenic Purpura
20.When should treatment begin for strongly suspected immune TTP?
When pretest probability is high, collect plasma for ADAMTS13 activity and inhibitor testing before plasma exchange or blood-product treatment, then initiate therapeutic plasma exchange and corticosteroids without awaiting the result. Plasma exchange addresses the circulating deficiency and inhibitor environment, while corticosteroids target immune activity. Decisions about early caplacizumab depend on probability and access to timely ADAMTS13 testing. Sampling and treatment should be coordinated so diagnostic preservation does not create a dangerous delay.
Apply it
A patient with a highly convincing TTP presentation has an ADAMTS13 result expected in two days. Draw the pretreatment sample immediately, then start plasma exchange and corticosteroids rather than waiting for laboratory confirmation.
Common pitfall: Waiting for the send-out result can permit ongoing microvascular injury. Collecting the first diagnostic sample after plasma therapy can also complicate interpretation of ADAMTS13 activity.
ISTH Guidelines for the Diagnosis of Thrombotic Thrombocytopenic Purpura
21.Which pattern distinguishes consumptive DIC from isolated thrombocytopenia?
DIC involves systemic coagulation activation, endothelial injury, and dysregulated fibrinolysis. Microvascular thrombosis can cause organ injury, while consumption of platelets and clotting factors can produce bleeding. In a compatible illness, falling platelets, prolonged prothrombin time, increased D-dimer or fibrin-degradation products, and falling fibrinogen support consumption across the hemostatic system. The pattern and its evolution matter more than an isolated abnormal value. Management must address the precipitating disease alongside necessary hemostatic support. See the [ISTH SSC's 2025 DIC recommendations](https://pure.amsterdamumc.nl/ws/files/149072767/Updated-definition-and-scoring-of-disseminated-intravascular-coagulation-in-2025.pdf).
Apply it
A patient with severe infection develops puncture-site bleeding, falling platelets and fibrinogen, prolonged PT, and markedly increased D-dimer. Evaluate DIC and treat the infection while assessing bleeding-related component needs.
Common pitfall: Schistocytes alone do not distinguish DIC from TTP. Liver disease and other causes of thrombocytopenia can mimic parts of the laboratory pattern, so clinical context and serial measurements are essential.
Hematology Blueprint — Certification Examination (CERT), January 2026
22.Which VWF levels support type 1 von Willebrand disease?
The joint diagnostic guideline supports a VWF level below 0.30 IU/mL regardless of bleeding, or below 0.50 IU/mL in a patient with abnormal bleeding, to confirm type 1 VWD. VWF level refers to antigen and/or platelet-dependent activity, interpreted within a compatible quantitative pattern. If the laboratory's lower reference limit is below 0.50 IU/mL, that limit is used. Test at baseline health when possible because bleeding, trauma, pregnancy, and other stress can increase VWF and conceal a lower baseline level.
Apply it
A patient with recurrent epistaxis and heavy menstrual bleeding has concordant antigen and activity near 0.40 IU/mL at baseline health, supporting type 1 VWD. A reassuring measurement obtained during major bleeding would warrant reassessment after recovery.
Common pitfall: Requiring a value below 0.30 IU/mL in every patient misses symptomatic quantitative deficiency. A low activity-to-antigen ratio instead raises concern for a qualitative subtype; an acute stress-state result can also be misleading.
ASH ISTH NHF WFH 2021 Guidelines on Diagnosis of von Willebrand Disease — Executive Summary
23.How does the VWF activity-to-antigen ratio suggest a qualitative defect?
VWF antigen estimates protein quantity, whereas platelet-dependent activity measures an important functional property. Disproportionately reduced activity produces a low activity-to-antigen ratio and suggests a qualitative defect. In patients with an abnormal initial screen, the guideline favors a ratio below 0.7 to support investigation for type 2A, 2B, or 2M VWD. The ratio identifies a diagnostic direction; additional studies are required to determine the specific subtype.
Apply it
VWF activity is 0.24 IU/mL and antigen is 0.60 IU/mL. Calculate 0.24 divided by 0.60, giving 0.40, and pursue a qualitative VWF abnormality rather than assuming a proportional quantitative reduction.
Common pitfall: A near-normal antigen concentration does not establish normal function. The low ratio does not by itself distinguish type 2A from type 2B or type 2M.
ASH ISTH NHF WFH 2021 Guidelines on Diagnosis of von Willebrand Disease — Executive Summary
24.Which findings distinguish inherited hemophilia A and B from an acquired factor inhibitor?
Hemophilia A is factor VIII deficiency; hemophilia B is factor IX deficiency. Both are usually X-linked and can cause joint or muscle bleeding from childhood. PT is generally normal; aPTT and specific factor assays investigate the intrinsic-pathway defect. Baseline activity classifies severity: severe <1%, moderate 1–5%, and mild >5% but <40%. Lifelong bleeding with an affected maternal relative favors inherited disease; new bleeding with a time-dependent inhibitor pattern favors acquired hemophilia. See [CDC diagnostic criteria](https://www.cdc.gov/hemophilia/testing/) and [inheritance and clinical features](https://www.cdc.gov/hemophilia/about/).
Apply it
A boy with recurrent hemarthroses and an affected maternal uncle has normal platelets and PT, prolonged aPTT, factor VIII 0.4%, and normal factor IX. These findings support severe hemophilia A. Isolated factor IX deficiency would indicate hemophilia B.
Common pitfall: An absent family history does not exclude inherited hemophilia, and females can be affected. Low factor VIII alone does not establish inheritance; assess VWD and an inhibitor when indicated.
Hematology Blueprint — Certification Examination (CERT), January 2026 · International Recommendations on the Diagnosis and Treatment of Acquired Hemophilia A
25.When can an adult with ITP be observed, and when should treatment be reconsidered?
In newly diagnosed adult ITP with no more than minor mucocutaneous bleeding, ASH supports observation when platelets are at least 30 × 10^9/L; below 30 × 10^9/L, treatment is generally favored. These thresholds require adjustment for bleeding, age, anticoagulant use, procedures, and other risks. For adults requiring initial therapy, the 2026 update conditionally favors corticosteroids combined with rituximab or a thrombopoietic agent over corticosteroids alone when available. After inadequate initial corticosteroid-based treatment, a thrombopoietic agent is recommended and rituximab is another suggested option. See [ASH's 2026 ITP recommendation summary](https://www.hematology.org/-/media/hematology/files/clinicians/guidelines/ash-itp-summary-of-changes_20260827.pdf).
Apply it
An adult with established ITP has platelets 45 × 10^9/L, only scattered petechiae, no anticoagulant use, and no planned procedure. Observation with follow-up can avoid unnecessary drug toxicity; new significant bleeding would change the decision.
Common pitfall: A platelet threshold is not a complete bleeding-risk assessment. These observation recommendations do not describe emergency management of major or life-threatening bleeding.
Hematology Blueprint — Certification Examination (CERT), January 2026
26.Why does an incubated mixing study matter in acquired hemophilia A?
A mixing study combines patient plasma with normal plasma to assess whether a prolonged aPTT corrects. Factor VIII autoantibodies can act in a time- and temperature-dependent manner, so immediate correction may be followed by prolongation after incubation. This pattern raises suspicion for an inhibitor but does not independently establish or exclude acquired hemophilia A. Factor activity and inhibitor testing should proceed alongside mixing studies when the clinical presentation is concerning.
Apply it
A patient with new extensive bruising has an isolated prolonged aPTT. The mixture initially corrects but becomes prolonged after two hours. Investigate a time-dependent factor VIII inhibitor rather than concluding that immediate correction proves simple deficiency.
Common pitfall: An immediate mixing result alone may miss a time-dependent inhibitor. Mixing studies are imperfectly standardized and cannot replace specific factor VIII and inhibitor investigations.
International Recommendations on the Diagnosis and Treatment of Acquired Hemophilia A
27.Which tests confirm a suspected acquired factor VIII inhibitor?
Acquired hemophilia A is supported by reduced factor VIII activity and evidence of an inhibitor, assessed with a Bethesda assay and/or an anti-factor VIII immunoassay. The Nijmegen modification improves specificity for low-titer inhibitors. Because autoantibody kinetics can be nonlinear and lupus anticoagulant can interfere with some assays, results require technical context. Chromogenic factor VIII testing can help resolve interference. Lupus anticoagulant does not exclude a coexisting factor VIII autoantibody, particularly when new soft-tissue bleeding is present.
Apply it
A patient with spontaneous muscle bleeding has factor VIII activity of 2% and an isolated prolonged aPTT. Measure factor VIII inhibitor activity and consider an anti-factor VIII immunoassay to establish the specific acquired inhibitor.
Common pitfall: A prolonged aPTT is not specific for acquired hemophilia. A low-positive inhibitor result can also require evaluation for assay interference rather than immediate uncritical acceptance.
International Recommendations on the Diagnosis and Treatment of Acquired Hemophilia A
28.How do persistent antiphospholipid antibodies influence thrombosis assessment and treatment?
APS assessment connects a compatible clinical event with persistent antiphospholipid antibodies. Relevant tests include lupus anticoagulant, anticardiolipin, and anti-β2-glycoprotein I antibodies; persistence means positivity on at least two occasions at least 12 weeks apart. A single transient positive result does not establish APS. Triple positivity identifies a high-risk profile. EULAR recommends avoiding rivaroxaban in triple-positive APS because of recurrent-event risk, making antibody profile consequential when selecting long-term anticoagulation. See the [EULAR APS management recommendations](https://pmc.ncbi.nlm.nih.gov/articles/PMC11034817/).
Apply it
A patient with prior thrombosis has all three antibody tests persistently positive 14 weeks apart and asks to switch from a vitamin K antagonist to rivaroxaban. Recognize high-risk triple-positive APS and avoid that switch.
Common pitfall: The word anticoagulant in lupus anticoagulant describes an assay effect and does not imply protection from thrombosis. Antibody positivity alone is not equivalent to a clinical APS diagnosis.
Hematology Blueprint — Certification Examination (CERT), January 2026
29.Why is LMWH generally preferred for acute pregnancy-associated VTE?
Low-molecular-weight heparin provides anticoagulation without crossing the placenta and is preferred over unfractionated heparin for most acute pregnancy-associated VTE because of its maternal safety profile. Vitamin K antagonists cross the placenta and can harm the fetus, while direct oral anticoagulants lack an appropriate established pregnancy role. The decision combines maternal thrombosis treatment with fetal exposure, rather than choosing solely on convenience or extrapolating routine nonpregnant VTE prescribing.
Apply it
A pregnant patient with adequate renal function has a newly confirmed proximal deep-vein thrombosis and no contraindication to anticoagulation. Choose LMWH while coordinating obstetric care and a plan for anticoagulation around delivery.
Common pitfall: An oral drug's convenience does not establish pregnancy safety. Warfarin's postpartum usefulness should not be extrapolated to routine treatment of VTE during pregnancy.
30.How does the trigger for a previous VTE guide pregnancy prophylaxis?
The ASH pregnancy approach distinguishes previous unprovoked or hormonally associated VTE from VTE caused by a resolved nonhormonal temporary factor. Prior unprovoked or hormonally associated events support antepartum and postpartum prophylaxis. A prior event from a resolved nonhormonal temporary trigger, without other risk factors, generally supports postpartum prophylaxis without routine antepartum prophylaxis. The original event's circumstances therefore change prevention decisions even when the previous clot occurred many years earlier.
Apply it
A patient planning pregnancy previously had a pulmonary embolism while using estrogen-containing contraception. Classify the event as hormonally associated and discuss prophylaxis during pregnancy and postpartum rather than treating it as a resolved surgical trigger.
Common pitfall: Labeling all previous events simply 'provoked' loses the distinction between hormonal and nonhormonal triggers. Additional current risk factors can also change an otherwise lower-risk assessment.
31.Which anticoagulants are supported during breastfeeding?
Pregnancy and breastfeeding involve different exposure pathways. ASH identifies options including LMWH, unfractionated heparin, and warfarin as acceptable during breastfeeding when anticoagulation is indicated. Heparins have properties that limit clinically important infant exposure, and warfarin has reassuring lactation experience. The cited guideline recommends against direct-acting oral anticoagulants during breastfeeding because evidence is insufficient. Treatment selection must therefore be reconsidered after delivery rather than simply carrying forward pregnancy restrictions unchanged.
Apply it
A postpartum patient requires ongoing anticoagulation and wants to breastfeed but finds injections burdensome. Discuss warfarin as an oral option with established breastfeeding compatibility, including the monitoring needed for safe and effective treatment.
Common pitfall: Assuming that every pregnancy restriction persists during lactation incorrectly excludes warfarin. Conversely, low reported milk concentrations alone do not establish adequate safety evidence for every oral anticoagulant.
Hematologic Neoplastic Disorders35%
32.How does BCR::ABL1 connect CML diagnosis with targeted treatment?
CML is driven by the BCR::ABL1 fusion, which encodes an abnormal tyrosine kinase and provides a target for kinase-inhibitor therapy. Demonstrating the fusion links a compatible myeloid proliferation to its defining molecular mechanism. Leukocytosis or splenomegaly alone cannot supply that specificity. The same disease marker can then be followed during treatment, connecting diagnostic classification, pharmacology, and response assessment through a single biologically meaningful abnormality.
Apply it
A patient with persistent myeloid leukocytosis and splenomegaly has BCR::ABL1 detected. Use the molecular result to establish the relevant disease pathway and explain why a BCR::ABL1-directed tyrosine kinase inhibitor is appropriate.
Common pitfall: Treating all myeloproliferative neoplasms as molecularly interchangeable misses the specific CML driver. A high white-cell count alone does not identify the target or establish the diagnosis.
NCI: Chronic Myeloid Leukemia Treatment (PDQ), Health Professional Version
33.How should molecular response in CML be interpreted?
Quantitative BCR::ABL1 measurement assesses residual molecular disease beyond normalization of blood counts. On the International Scale, major molecular response corresponds to BCR::ABL1 at or below 0.1%; deeper responses have lower transcript levels. Interpretation depends on treatment duration, serial change, and measurement context. A normal complete blood count does not establish molecular remission, and an isolated transcript result should be interpreted within the response trajectory rather than automatically triggering a treatment change.
Apply it
After treatment, a patient's blood counts normalize while BCR::ABL1 remains 0.8% on the International Scale. Recognize hematologic improvement without major molecular response, then assess the time point and serial results before determining the next step.
Common pitfall: Confusing hematologic and molecular response overstates disease control. A single detectable result is also not equivalent to treatment failure without its timing, trend, and clinical context.
NCI: Chronic Myeloid Leukemia Treatment (PDQ), Health Professional Version
34.Which findings distinguish polycythemia vera from secondary erythrocytosis?
Using the International Consensus Classification features summarized by NCI, evaluate hemoglobin >16.5 g/dL in men or >16.0 g/dL in women, hematocrit >49% in men or >48% in women, or increased red-cell mass. Specific clonal findings are JAK2 V617F or exon 12 variants and age-adjusted marrow hypercellularity with panmyelosis: erythroid, granulocytic, and megakaryocytic proliferation. Subnormal serum erythropoietin is a minor criterion. Integrate these findings rather than diagnosing PV from an elevated hematocrit or JAK2 result alone. Assess hypoxia and other secondary erythropoietic stimuli concurrently.
Apply it
A man has hematocrit 53%, JAK2 V617F, subnormal erythropoietin, and marrow panmyelosis. These concordant findings favor PV. Similar erythrocytosis in a hypoxemic patient without that clonal pattern requires assessment for a secondary cause.
Common pitfall: The diagnostic hematocrit threshold differs from the treatment target below 45%. JAK2 variants also occur in other myeloproliferative neoplasms, so the blood-count and marrow phenotype remain essential.
35.Why is hematocrit control below 45% important in polycythemia vera?
PV treatment includes controlling excessive red-cell production to reduce vascular complications. The NCI summary identifies a hematocrit target below 45%, supported by randomized evidence showing fewer cardiovascular deaths and major thrombotic events with tighter control. Phlebotomy and, when indicated, cytoreductive treatment are tools for achieving control. The decision is tied to prevention of important clinical outcomes rather than simply moving the hematocrit closer to the laboratory reference range.
Apply it
A patient with established PV feels well but has a hematocrit of 49%. Symptoms alone do not establish adequate control; adjust the management plan to achieve the supported hematocrit target and reduce vascular risk.
Common pitfall: Accepting a mildly elevated hematocrit because the patient is asymptomatic overlooks thrombosis prevention. The target is disease-specific and should not be indiscriminately applied to secondary erythrocytosis.
36.Which persistent cytopenias and morphological findings should prompt evaluation for MDS?
MDS combines ineffective, abnormal hematopoiesis with one or more cytopenias. Macrocytic anemia despite adequate vitamin B12 and folate, hypogranular or hyposegmented neutrophils, and small abnormal megakaryocytes are useful clues. Marrow morphology, blast assessment, and cytogenetics help establish and stratify the disorder after reversible explanations are assessed. Cytopenia severity, marrow blasts, and cytogenetic abnormalities influence prognosis; a low circulating count can coexist with a hypercellular marrow because production is ineffective. See [NCI's MDS diagnostic and prognostic summary](https://www.cancer.gov/types/myeloproliferative/hp/myelodysplastic-treatment-pdq).
Apply it
An older adult has persistent macrocytic anemia and neutropenia, normal vitamin levels, and hypogranular neutrophils with abnormal nuclear segmentation. Obtain marrow and genetic assessment rather than treating the MCV alone as evidence of nutritional deficiency.
Common pitfall: Macrocytosis alone does not establish MDS. A hypocellular marrow also does not exclude MDS, so cellularity must be interpreted with dysplasia, blasts, and clonal findings.
Hematology Blueprint — Certification Examination (CERT), January 2026
37.How does PML::RARA explain ATRA sensitivity in APL?
Acute promyelocytic leukemia is usually characterized by PML::RARA, commonly arising from t(15;17). The abnormal retinoic-acid receptor pathway contributes to arrested myeloid differentiation. All-trans retinoic acid acts as a differentiating agent, connecting the defining genetic lesion with a disease-specific treatment principle. PML::RARA may be cryptic on conventional cytogenetics, so molecular or fluorescence-based testing can be needed when morphology and the clinical presentation strongly suggest APL.
Apply it
Abnormal promyelocytes and a compatible molecular result establish PML::RARA-positive APL. Explain ATRA as a treatment that promotes differentiation of the leukemic population rather than as a nonspecific substitute for every AML therapy.
Common pitfall: A normal-looking conventional karyotype does not exclude a cryptic fusion. ATRA sensitivity should not be generalized to all acute myeloid leukemia subtypes without their biological context.
NCI: Acute Myeloid Leukemia Treatment (PDQ), Health Professional Version
38.What must begin immediately when APL is suspected?
Suspected APL is a medical emergency: start all-trans retinoic acid immediately, before molecular confirmation, while arranging rapid PML::RARA testing and aggressive coagulation support. ATRA can be discontinued if genetic testing excludes APL. ELN recommends platelet, cryoprecipitate/fibrinogen, and plasma support to maintain platelets above 30–50 × 10^9/L, fibrinogen above 100–150 mg/dL, and INR below 1.5. Monitor platelets, PT, aPTT, thrombin time, fibrinogen, and fibrin-degradation products at least daily and more frequently as needed until coagulopathy resolves. Avoid invasive procedures while hemorrhagic risk is high. See the [ELN APL recommendations](https://pmc.ncbi.nlm.nih.gov/articles/PMC6509567/).
Apply it
Bleeding, low fibrinogen, and abnormal promyelocytes with bundles of Auer rods warrant immediate ATRA and blood-product support while confirmatory testing proceeds. Do not wait for the fusion result to initiate these measures.
Common pitfall: Urgent testing and supportive care alone omit the decisive immediate disease-directed treatment. Microgranular APL may lack conspicuous dense granules, so their absence cannot provide reassurance.
NCI: Acute Myeloid Leukemia Treatment (PDQ), Health Professional Version
39.Why do genetic findings matter beyond the blast count in AML?
AML is biologically heterogeneous, and recurrent genetic abnormalities influence classification, prognosis, and treatment selection. A blast count describes disease burden but cannot capture those differences. Core-binding-factor fusions, PML::RARA, and other molecular abnormalities identify distinct disease groups with differing implications. A rigorous assessment therefore integrates morphology, immunophenotype, cytogenetics, and molecular testing. Avoid assuming that patients with similar marrow blast percentages necessarily have equivalent biology, expected outcomes, or suitable treatment approaches.
Apply it
Two patients have similar marrow blast percentages, but one has a core-binding-factor fusion and the other has adverse molecular findings. Use the genetic information to refine risk assessment instead of assigning identical prognoses from blast burden.
Common pitfall: A single numerical blast percentage is an incomplete disease description. Genetic classifications also evolve, so older terminology should not be treated as universally interchangeable with current categories.
NCI: Acute Myeloid Leukemia Treatment (PDQ), Health Professional Version
40.Why does ALL treatment require CNS-directed therapy even when the CSF is initially negative?
The central nervous system can act as a sanctuary for lymphoblasts, so systemic remission does not establish eradication of CNS disease. ALL treatment incorporates CNS prophylaxis early and during subsequent phases, using intrathecal treatment and/or CNS-penetrating systemic therapy according to the regimen. A negative initial CSF examination does not remove this preventive requirement. Disease characterization also includes immunophenotype and genetics, which affect systemic treatment selection. See [NCI's ALL treatment summary](https://www.cancer.gov/types/leukemia/hp/adult-all-treatment-pdq).
Apply it
An adult with newly diagnosed ALL has no neurologic symptoms and negative CSF cytology. Retain the protocol's CNS-directed prophylaxis rather than omitting it because overt CNS involvement was not detected.
Common pitfall: Marrow remission and a negative CSF sample do not establish protection against later CNS relapse. Prophylaxis is distinct from the more intensive treatment required for documented CNS leukemia.
Hematology Blueprint — Certification Examination (CERT), January 2026
41.Which findings separate monoclonal B-cell lymphocytosis from CLL?
Monoclonal B-cell lymphocytosis is defined by a circulating clonal B-cell population below 5 × 10^9/L without features such as lymphadenopathy or splenomegaly. Many cases share the immunophenotype of CLL, so clonality or phenotype alone does not establish CLL. The relevant count is the clonal B-cell count rather than the total leukocyte count. Clinical evidence of tissue disease or disease-related cytopenia requires a broader classification assessment.
Apply it
An asymptomatic patient has 3.1 × 10^9/L clonal B cells with a CLL-like phenotype, normal counts otherwise, and no adenopathy or organ enlargement. Classify the finding as MBL rather than diagnosing CLL from phenotype alone.
Common pitfall: Using total lymphocytes instead of clonal B cells can misapply the threshold. A small circulating clone does not exclude clinically important tissue disease when examination findings suggest it.
NCI: Chronic Lymphocytic Leukemia Treatment (PDQ), Health Professional Version
42.When is observation appropriate in newly diagnosed CLL, and how does TP53 status affect treatment selection?
Observe asymptomatic CLL without clinically significant progression, marrow failure, or disease-related complications. Follow symptoms, examination findings, and blood counts. A pathogenic TP53 mutation or del(17p) alone does not require treatment. Once treatment is indicated, these abnormalities predict poor responses and short remissions with conventional chemoimmunotherapy. Use a chemotherapy-free targeted approach, such as acalabrutinib or zanubrutinib, which inhibit BTK signaling, or venetoclax-based therapy, which inhibits BCL2 to promote apoptosis.
Apply it
A patient with del(17p), stable lymphocytosis, preserved hemoglobin and platelets, and no symptoms remains under observation. If symptomatic progressive adenopathy develops, consider targeted treatment. Assess bleeding and atrial-fibrillation risk with BTK inhibitors; venetoclax requires tumor-lysis risk assessment, prophylaxis, dose escalation, and laboratory monitoring.
Common pitfall: Do not confuse a marker that changes treatment selection with an indication to start treatment. TP53-altered disease can respond to targeted agents despite chemotherapy resistance. Drug choice also depends on comorbidities, interacting medications, and the feasibility of monitoring.
NCI: Chronic Lymphocytic Leukemia Treatment (PDQ), Health Professional Version
43.What limits conclusions about a leukemia treatment compared with historical controls?
A historical-control comparison evaluates a treated cohort against patients treated earlier rather than against a concurrently randomized control group. Differences in eligibility, disease risk, supportive care, follow-up, and accompanying treatment can confound the apparent benefit. The NCI ALL summary illustrates this problem with an imatinib-containing regimen compared with an earlier cohort: the study was nonrandomized, relatively small, and also changed asparaginase use during enrollment. Improved survival supported further investigation but could not isolate the causal contribution of imatinib as confidently as a well-conducted randomized comparison.
Apply it
When reviewing a leukemia study reporting better survival than historical controls, compare baseline risk, eligibility, follow-up, and the complete treatment regimens. In the described ALL study, adding imatinib and changing asparaginase exposure mean that treatment differences extend beyond the drug being evaluated. Describe the observed association and its limitations before attributing the entire survival difference to one agent.
Common pitfall: A small P value does not remove confounding or make a nonrandomized comparison equivalent to randomization. Likewise, a higher response rate does not by itself demonstrate longer survival; assess the actual endpoint, response duration, toxicity, and study design.
NCI: Chronic Lymphocytic Leukemia Treatment (PDQ), Health Professional Version · Acute Lymphoblastic Leukemia Treatment (PDQ®) - NCI
44.Which numerical CRAB findings qualify as myeloma-defining organ injury?
IMWG criteria require clonal marrow plasma cells at least 10% or a biopsy-proven plasmacytoma, plus a myeloma-defining event. Attributable CRAB thresholds are calcium >1 mg/dL above the upper limit of normal or >11 mg/dL; creatinine clearance <40 mL/min or creatinine >2 mg/dL; hemoglobin >2 g/dL below the lower limit of normal or <10 g/dL; or osteolytic bone disease. CT or PET/CT must show osteolytic destruction at least 5 mm; PET uptake alone is insufficient. If clonal marrow plasma cells are below 10%, more than one bone lesion is required to distinguish myeloma from solitary plasmacytoma with minimal marrow involvement.
Apply it
A patient has 18% clonal marrow plasma cells and an attributable 8-mm osteolytic lesion on CT. This establishes a myeloma-defining event despite normal calcium and renal function. One such lesion with only 6% marrow involvement would require assessment for solitary plasmacytoma.
Common pitfall: Unrelated anemia or renal disease cannot be counted as attributable injury. Osteoporosis or compression fractures without lytic destruction do not meet the bone-disease criterion.
IMWG Criteria for the Diagnosis of MM | Inl Myeloma Fn · NCI: Plasma Cell Neoplasms Treatment (PDQ), Health Professional Version
45.Which complete biomarker alternatives define myeloma before CRAB injury?
With the underlying requirement of at least 10% clonal marrow plasma cells or a biopsy-proven plasmacytoma, any one of three IMWG biomarkers can establish active myeloma: at least 60% clonal marrow plasma cells; an involved-to-uninvolved serum free-light-chain ratio at least 100 with involved light chain at least 100 mg/L; or more than one MRI focal lesion, each at least 5 mm. These alternatives permit classification before conventional CRAB injury appears. Both the light-chain concentration requirement and MRI lesion number and size are essential.
Apply it
A patient with 15% clonal marrow plasma cells has a free-light-chain ratio of 120 but an involved light chain of 75 mg/L. That result does not meet the light-chain biomarker. By contrast, 65% clonal marrow plasma cells independently meets a qualifying biomarker.
Common pitfall: A ratio of 100 alone is insufficient. One MRI focal lesion, even if at least 5 mm, also does not meet the MRI biomarker.
IMWG Criteria for the Diagnosis of MM | Inl Myeloma Fn · NCI: Plasma Cell Neoplasms Treatment (PDQ), Health Professional Version
46.Which criteria distinguish non-IgM MGUS, smoldering myeloma, and active myeloma?
Non-IgM MGUS requires serum monoclonal protein below 3 g/dL, clonal marrow plasma cells below 10%, and no attributable CRAB organ injury or amyloidosis. Smoldering myeloma requires serum IgG/IgA monoclonal protein at least 3 g/dL or urinary monoclonal protein at least 500 mg/24 hours and/or clonal marrow plasma cells at least 10% but below 60%, with neither myeloma-defining events nor amyloidosis. Active myeloma requires at least 10% clonal marrow plasma cells or a biopsy-proven plasmacytoma plus attributable CRAB injury or a qualifying biomarker. Biomarkers are marrow clonal plasma cells at least 60%; an involved/uninvolved serum free-light-chain ratio at least 100 with involved light chain at least 100 mg/L; or more than one MRI focal lesion, each at least 5 mm.
Apply it
A patient has 15% clonal marrow plasma cells, an IgG monoclonal protein of 1.2 g/dL, a free-light-chain ratio of 8, no qualifying imaging lesions, no attributable CRAB injury, and no associated amyloidosis after appropriate assessment. This meets smoldering myeloma criteria through marrow burden despite the serum protein being below 3 g/dL. If marrow involvement instead reaches 60%, the biomarker establishes active myeloma even without symptoms.
Common pitfall: Absence of CRAB findings alone does not establish MGUS or smoldering disease: evaluate qualifying biomarkers and exclude attributable amyloidosis. AL amyloidosis can accompany a small plasma-cell clone and requires separate recognition. With marrow plasma cells below 10%, more than one bone lesion is required to distinguish myeloma from solitary plasmacytoma with minimal marrow involvement.
NCI: Plasma Cell Neoplasms Treatment (PDQ), Health Professional Version · IMWG Criteria for the Diagnosis of MM | Inl Myeloma Fn
47.How does an aggressive B-cell lymphoma diagnosis change the initial management decision?
A rapidly growing mass requires adequate tissue assessment to distinguish DLBCL and other aggressive B-cell lymphomas from indolent lymphoma and reactive disease. Histology and immunophenotyping determine the disease entity; stage and patient fitness then guide treatment. DLBCL can be treated with curative intent using combination immunochemotherapy, including R-CHOP or Pola-R-CHP in appropriate settings. The observation strategy used for selected indolent lymphomas should not be transferred automatically to an aggressive histology. Assess tumor-lysis risk before treatment. See [NCI's aggressive B-cell lymphoma summary](https://www.cancer.gov/types/lymphoma/hp/aggressive-b-cell-lymphoma-treatment-pdq).
Apply it
Biopsy of a rapidly enlarging nodal mass establishes DLBCL. Arrange staging, fitness assessment, and curative-intent treatment planning rather than prolonged observation based on the absence of major symptoms.
Common pitfall: Rapid growth or high PET uptake alone does not establish the histological subtype. Conversely, advanced stage does not by itself eliminate the possibility of cure in DLBCL.
Hematology Blueprint — Certification Examination (CERT), January 2026
48.When can follicular lymphoma be managed with observation?
Selected patients with indolent follicular lymphoma can undergo observation when disease burden and symptoms do not require treatment. Histologic diagnosis establishes the entity, while clinical behavior determines the immediate need for intervention. Observation includes planned reassessment for symptoms, enlarging disease, organ compromise, and changing biology. The key distinction is between an established malignancy and a current treatment indication, rather than assuming that every lymphoma diagnosis requires immediate systemic therapy.
Apply it
A patient has biopsy-confirmed follicular lymphoma, small stable nodes, no systemic symptoms, and no threatened organ function. Discuss observation with a clear follow-up plan rather than treating the diagnostic label alone as an immediate indication.
Common pitfall: Observation is appropriate only for selected presentations. Bulky, symptomatic, organ-threatening, or rapidly changing disease requires renewed assessment rather than automatic continuation of the initial strategy.
49.Which changes in follicular lymphoma should prompt a new biopsy?
Indolent lymphoma can transform to a more aggressive histology. Rapid or disproportionate nodal enlargement, new systemic symptoms, and a changed clinical tempo raise concern that the original biopsy no longer describes the active disease. A new tissue sample is important because treatment depends on current histology. Imaging can identify a suspicious site but does not replace histologic confirmation. The decision should follow the most concerning current lesion rather than convenience alone.
Apply it
A patient with previously stable follicular lymphoma develops one rapidly enlarging node and new night sweats. Biopsy the concerning lesion to assess transformation before assuming ordinary indolent relapse and selecting a familiar previous treatment.
Common pitfall: Repeating treatment from the original diagnosis without reassessing changed biology can undertreat transformed disease. Increased metabolic activity is a targeting clue, not histologic proof on its own.
50.Which Hodgkin lymphoma findings establish diagnosis, stage, and the formal B designation?
Persistent painless lymphadenopathy requires tissue diagnosis, preferably an excisional biopsy when feasible; clinical appearance alone cannot establish Hodgkin lymphoma. After diagnosis, PET/CT helps define disease extent. Document general symptoms, but apply the formal B criteria separately: unexplained fever above 38°C, drenching recurrent night sweats, or unexplained weight loss greater than 10% of body weight over the preceding six months. Any one qualifying symptom supports the B designation. Fatigue and pruritus remain clinically relevant but do not independently satisfy these criteria. See [NCI's formal B-designation definition](https://www.cancer.gov/types/lymphoma/hp/adult-hodgkin-treatment-pdq).
Apply it
A patient with confirmed Hodgkin lymphoma has recurrent unexplained temperatures of 38.4°C but no night sweats or weight loss. Fever alone supports the B designation. Unexplained weight loss of exactly 10% alone would not meet NCI's formal greater-than-10% criterion.
Common pitfall: Do not substitute general symptom descriptions for staging thresholds: the fever must be unexplained and above 38°C, and qualifying weight loss must be unexplained and greater than 10% over six months. PET avidity does not replace diagnostic tissue.
51.How does tumor lysis produce its characteristic biochemical pattern?
Rapid tumor-cell breakdown releases potassium, phosphate, and nucleic-acid products. The resulting pattern includes hyperkalemia, hyperphosphatemia, hyperuricemia, and secondary hypocalcemia. Kidney injury can worsen clearance and amplify the disturbance. Risk depends on disease burden, proliferation, treatment sensitivity, baseline renal function, and other clinical factors. Recognizing the pattern links the laboratory abnormalities to a common mechanism and supports preventive planning before treatment rather than reacting only after symptomatic electrolyte injury.
Apply it
After treatment of a bulky, highly responsive malignancy, potassium, phosphate, and urate rise while calcium falls. Recognize tumor lysis and assess renal function and clinical consequences rather than evaluating each abnormality as an unrelated event.
Common pitfall: Tumor lysis can occur before treatment as well as afterward. A reassuring single baseline measurement does not eliminate risk during a period of rapid cellular breakdown.
Cancer Institute NSW eviQ: Prevention of Tumour Lysis Syndrome
52.Why does G6PD status matter when selecting urate-lowering treatment?
Allopurinol limits formation of new uric acid, whereas rasburicase enzymatically breaks down existing uric acid. These mechanisms are not interchangeable when urate is already elevated. Rasburicase carries an important hemolytic risk in G6PD deficiency; the eviQ guidance calls for testing before treatment and states that it should not be administered to deficient patients. Urate reduction must therefore be selected with both the biochemical problem and the patient's red-cell vulnerability in mind.
Apply it
A patient at high tumor-lysis risk has known G6PD deficiency and marked hyperuricemia. Avoid rasburicase and construct an alternative prevention and management plan that accounts for the existing urate burden and renal function.
Common pitfall: Choosing rasburicase solely because it rapidly lowers urate ignores a consequential contraindication. Allopurinol also does not directly remove uric acid already present in the circulation.
Cancer Institute NSW eviQ: Prevention of Tumour Lysis Syndrome
Transfusion Medicine5%
53.Which findings favor TACO over TRALI after transfusion?
TACO reflects hydrostatic pulmonary edema from circulatory overload, whereas TRALI involves noncardiogenic pulmonary injury. Both can produce hypoxemia and bilateral infiltrates. Hypertension, positive fluid balance, evidence of cardiac congestion, and improvement with diuresis favor TACO. Natriuretic peptides can contribute but are not independently definitive. The distinction requires integration of the patient's baseline cardiac and renal status, fluid exposure, examination, and response rather than interpreting the chest radiograph alone.
Apply it
An older patient with heart failure develops dyspnea, hypertension, raised jugular venous pressure, and bilateral edema during transfusion. Positive fluid balance and improvement after diuresis favor TACO over an isolated permeability-mediated lung injury.
Common pitfall: Bilateral infiltrates do not distinguish TACO from TRALI. Some features overlap, and both conditions can coexist, so one biomarker or isolated sign should not determine classification.
AABB Association Bulletin 15-02: Transfusion-Associated Circulatory Overload, Revised March 2026
54.Which transfusion circumstances require recognition of an irradiation indication?
Irradiation of cellular blood components prevents viable donor T lymphocytes from proliferating and causing transfusion-associated GVHD. Concrete indications include cellular components donated by a blood relative, components selected for HLA compatibility, and transfusion support for relevant marrow or peripheral blood progenitor-cell transplant recipients. Intrauterine transfusion is another recognized setting. These indications arise from the recipient or donor–recipient immune relationship; ABO compatibility and leukocyte reduction do not provide equivalent protection against donor T-cell proliferation.
Apply it
A patient's brother donates an otherwise compatible red-cell unit for the patient. Recognize the related-donor indication and ensure that the cellular component is irradiated before transfusion, even if the recipient has no known immunodeficiency.
Common pitfall: Leukocyte reduction does not replace irradiation for these indications. Irradiation also does not correct ABO incompatibility or prevent circulatory overload.
55.How can an iron-deficient patient be supported when transfusion is declined?
Management starts by understanding the patient's specific choices and identifying the mechanism and severity of anemia. For iron deficiency, replace iron through a feasible route and investigate ongoing loss or impaired absorption. Intravenous iron can bypass gastrointestinal limitations, while treatment of the bleeding source addresses continued depletion. The pace of endogenous red-cell production differs from transfusion's immediate effect, so monitoring and decisions must account for symptoms, physiological reserve, and the clinical trajectory.
Apply it
A stable patient with iron-deficiency anemia declines red-cell transfusion but accepts intravenous iron and endoscopic evaluation. Document these preferences, replace iron, investigate bleeding, and monitor the response with an explicit plan for clinical deterioration.
Common pitfall: Assuming that refusal of red cells means refusal of every intervention can unnecessarily restrict care. Iron replacement also cannot be expected to provide an immediate transfusion-equivalent hemoglobin increase.
NHLBI: Iron-Deficiency Anemia · Hematology Blueprint — Certification Examination (CERT), January 2026
Cellular Therapy8%
56.How do autologous and allogeneic transplantation differ biologically?
Autologous transplantation returns the patient's own blood-forming stem cells after intensive treatment, supporting hematopoietic recovery. Allogeneic transplantation uses donor cells and introduces a donor immune system that can attack residual malignancy but can also injure host tissues. This creates different benefit and toxicity profiles. The choice involves disease characteristics, patient fitness, available cells or donors, and competing treatments rather than assuming that either approach is simply a stronger version of the other.
Apply it
A patient compares an autologous rescue strategy with an allogeneic transplant. Explain that the latter adds donor immune effects, including potential graft-versus-leukemia activity and GVHD risk, whereas autologous rescue uses the patient's own collected cells.
Common pitfall: Equating the two procedures because both infuse stem cells overlooks the donor immune relationship. Allogeneic transplantation's immune benefit comes with risks that autologous rescue does not share.
57.Why is hematopoietic recovery central to transplant supportive care?
Conditioning treatment can damage blood-forming capacity, while infused stem cells provide a source for subsequent hematopoietic recovery. Until recovery occurs, infection and bleeding risks are important consequences of impaired blood-cell production. Recovery of circulating counts is therefore a meaningful milestone, but it does not establish complete immune reconstitution or cure of the underlying disease. Supportive care and longer-term follow-up address different phases of risk rather than ending when a single count improves.
Apply it
A patient recovering from conditioning has low neutrophils and platelets before count recovery. Link infection and bleeding precautions to impaired hematopoiesis, then reassess ongoing risks as counts recover rather than assuming all transplant-related vulnerability has ended.
Common pitfall: A stem-cell infusion does not restore normal blood production immediately. Later count recovery also does not exclude infection, organ toxicity, or recurrence of the original malignancy.
58.Which donor–host immune direction defines graft-versus-host disease?
In GVHD, donor-derived immune cells recognize recipient tissues as foreign and attack them. Skin, liver, and intestinal injury are important manifestations. This direction is the reverse of host-mediated rejection of donor cells. The diagnosis requires clinical assessment because infection, treatment toxicity, and other transplant complications can produce overlapping findings. Timing provides context, but a calendar boundary alone is an incomplete explanation of the patient's organ-injury pattern or immune mechanism.
Apply it
After allogeneic transplantation and initial blood-count recovery, a patient develops rash and substantial diarrhea. Assess GVHD alongside infectious and treatment-related explanations, recognizing that the relevant immune injury runs from donor cells toward recipient tissues.
Common pitfall: Calling GVHD rejection reverses the immune direction. Rash or diarrhea after transplantation is also not automatically GVHD without evaluating competing causes in the individual patient.
59.How does cytokine release syndrome follow CAR T-cell activation?
CAR T-cell therapy redirects immune cells against a target antigen. Strong immune activation can release large quantities of cytokines, causing cytokine release syndrome with fever and potentially hypotension or other organ dysfunction. Tocilizumab blocks IL-6 signaling and is used to control appropriate CRS presentations; corticosteroids may also be needed. Infection remains an important competing or coexisting explanation for fever after cellular therapy, so recognizing CRS does not remove the need for clinical evaluation.
Apply it
Soon after CAR T-cell infusion, a patient develops high fever and falling blood pressure. Assess CRS severity and infection concurrently, provide supportive care, and consider IL-6-directed treatment within the cellular-therapy management plan.
Common pitfall: Treating every postinfusion fever as uncomplicated infection can miss CRS, while labeling it CRS alone can miss infection. Tocilizumab targets a cytokine pathway rather than the tumor antigen.
60.How do neurologic findings guide ICANS treatment after CAR T-cell therapy?
ICANS can cause impaired language, attention, handwriting, and consciousness, with or without concurrent CRS. Assess the ICE score, arousal, seizures, motor findings, and cerebral edema while excluding other causes. An ICE score of 0–2 in an arousable patient can indicate grade 3 ICANS; an awake patient with global aphasia is not automatically grade 4. For ciltacabtagene autoleucel, FDA guidance directs corticosteroid treatment for grade 2 or higher ICANS and intensive care for severe toxicity, with antiseizure treatment or prophylaxis as appropriate. Tocilizumab addresses concurrent CRS and is insufficient alone for isolated ICANS.
Apply it
After systemic CRS resolves, a patient develops aphasia and an ICE score of 2 while remaining awake. Evaluate severe ICANS urgently, initiate product-appropriate corticosteroids and intensive neurological monitoring, and assess seizure risk rather than repeating tocilizumab alone.
Common pitfall: CRS resolution does not exclude subsequent ICANS. A low ICE score must be interpreted with arousal and other neurological findings, rather than assigning severity from speech impairment alone.
download · NCI: CAR T Cells — Engineering Immune Cells to Treat Cancer
What to focus on during revision
The following are CertMedbry study suggestions. Use the official outline to check the full scope of your examination.
- Use the official allocation to organize review: Hematopoietic System 25%, Coagulation 27%, Hematologic Neoplastic Disorders 35%, Transfusion Medicine 5%, and Cellular Therapy 8%. Within red-cell disorders, prioritize destruction disorders, allocated 15%, alongside production disorders, allocated 4%.
- Practise connecting a laboratory abnormality to its mechanism: iron stores versus availability, globin-chain deficiency versus iron deficiency, warm IgG-mediated versus cold complement-mediated hemolysis, antibody binding versus platelet activation, and VWF quantity versus function.
- Rehearse urgent decision sequences for suspected TTP, high-probability HIT, suspected APL requiring immediate ATRA, severe acute chest syndrome, DIC, tumor lysis, and cellular-therapy toxicities.
- Distinguish a diagnosis from a treatment indication in CLL, ITP, and indolent lymphoma; recognize when aggressive lymphoma requires prompt treatment planning and when plasma-cell findings meet complete myeloma criteria.
- Integrate pregnancy and contraception into thrombosis cases as overlapping clinical contexts; reassess anticoagulant choices separately during pregnancy and breastfeeding.
- Connect pancytopenia to production failure and marrow findings, distinguishing aplastic anemia, nutritional abnormalities, and MDS rather than assigning a diagnosis from low counts alone.
- Extend study beyond these selected concepts using the complete outline, including broader hemoglobinopathies and hemolytic disorders, white-cell disorders, HUS, inherited thrombophilia, other factor deficiencies, T-cell and NK-cell neoplasms, broader pharmacology, transplant supportive care, and clinical trial interpretation.
- Include blood-film and marrow morphology, radiographs, and other clinical media in review because the examination can require interpretation of illustrated findings.
A practical preparation plan
1. Map the full certification scope
Work through the January 2026 certification blueprint and mark each topic as secure, uncertain, or unstudied. Allocate initial study time approximately by the official domain weights, then adjust for demonstrated weaknesses without neglecting transfusion or cellular therapy.
2. Build mechanism-to-decision explanations
For each concept, explain the mechanism, decisive finding, next decision, and tempting alternative aloud. Compare thalassemia with iron deficiency, warm with cold autoimmune hemolysis, and inherited hemophilia with acquired inhibitors. Write the component scores and calculations for the 4Ts, VWF ratios, ADAMTS13 interpretation, PV findings, complete myeloma criteria, and CML molecular response.
3. Rehearse emergency sequences
Practise the order of sampling and treatment in suspected TTP, the immediate anticoagulant change in probable HIT, and immediate ATRA plus coagulation support in suspected APL. Apply severity and trajectory to severe acute chest syndrome, DIC, tumor lysis, TACO, CRS, and ICANS.
4. Complete and dissect the learning questions
Answer the 20 questions before reading explanations. For every missed or uncertain item, identify the overlooked cue and explain why each alternative is less appropriate. Use domain-level gaps to choose the next review topic; this short set cannot estimate examination readiness.
5. Use spaced recall and mixed cases
Review the flashcards repeatedly, recalling the reasoning before revealing the answer. Mix benign and malignant hematology cases, add pregnancy or transplant contexts, and practise interpreting findings without relying on a disease label supplied in advance.
6. Practise sustained examination pacing
Use longer mixed practice blocks after content review. Revisit uncertain decisions, interpret reference ranges in context, and develop a pacing and break strategy using the official session information summarized in the FAQs.
Use your sample score as a starting point
The free set contains 20 original practice questions. It is a small learning sample, not an official examination or a validated pass prediction. Review each explanation and its source before moving to another topic.
Start the free sampleOfficial sources and updates
- ABIM Blueprints
- Hematology Blueprint — Certification Examination (CERT), January 2026
- ABIM Internal Medicine & Subspecialty Policies — Hematology
- Register, Prepare and Take Your Subspecialty Certification Exam — Hematology
- NHLBI: Iron-Deficiency Anemia
- NHLBI: Vitamin B12–Deficiency Anemia
- MedlinePlus Genetics: Glucose-6-Phosphate Dehydrogenase Deficiency
- ICCS/ESCCA Consensus Guidelines for PNH Flow Cytometry, Part 4
- ASH: Sickle Cell Disease — Transfusion Support Pocket Guide
- ASH: Diagnosis and Management of Heparin-Induced Thrombocytopenia
- ISTH Guidelines for the Diagnosis of Thrombotic Thrombocytopenic Purpura
- ASH ISTH NHF WFH 2021 Guidelines on Diagnosis of von Willebrand Disease — Executive Summary
- International Recommendations on the Diagnosis and Treatment of Acquired Hemophilia A
- ASH: Venous Thromboembolism in the Context of Pregnancy
- NCI: Chronic Myeloid Leukemia Treatment (PDQ), Health Professional Version
- NCI: Acute Myeloid Leukemia Treatment (PDQ), Health Professional Version
- NCI: Chronic Lymphocytic Leukemia Treatment (PDQ), Health Professional Version
- NCI: Plasma Cell Neoplasms Treatment (PDQ), Health Professional Version
- NCI: Indolent B-Cell Non-Hodgkin Lymphoma Treatment (PDQ)
- NCI: Myeloproliferative Neoplasms Treatment (PDQ)
- Cancer Institute NSW eviQ: Prevention of Tumour Lysis Syndrome
- AABB Association Bulletin 15-02: Transfusion-Associated Circulatory Overload, Revised March 2026
- AABB: Irradiation
- NCI: Stem Cell and Bone Marrow Transplants for Cancer
- NCI: CAR T Cells — Engineering Immune Cells to Treat Cancer
- IMWG Criteria for the Diagnosis of MM | Inl Myeloma Fn
- The Double-edged Sword of Hepcidin - NIDDK
- download
- Anemia - Aplastic Anemia | NHLBI, NIH
- ASH Guidelines on Severe Acquired Aplastic Anemia - Hematology.org
- Aplastic Anemia - Hematology.org
- ash-itp-summary-of-changes_20260827.pdf
- Updated-definition-and-scoring-of-disseminated-intravascular-coagulation-in-2025.pdf
- Myelodysplastic Syndromes Treatment (PDQ®) - NCI
- Acute Lymphoblastic Leukemia Treatment (PDQ®) - NCI
- Aggressive B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®) - NCI
- Hodgkin Lymphoma Treatment (PDQ®) - NCI
- International Clinical Cytometry Society
- EULAR recommendations for the management of antiphospholipid syndrome in adults - PMC
- Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet - PMC
Confirm current eligibility, fees, scheduling and policies directly with the examination provider. CertMedbry is independent and is not endorsed by these organisations. How we handle content and corrections.